Burdo, Tricia H.
Chen, Chen
Kaminski, Rafal http://orcid.org/0000-0001-8827-6658
Sariyer, Ilker K.
Mancuso, Pietro http://orcid.org/0000-0001-7079-9848
Donadoni, Martina
Smith, Mandy D.
Sariyer, Rahsan
Caocci, Maurizio
Liao, Shuren
Liu, Hong
Huo, Wenwen
Zhao, Huaqing
Misamore, John
Lewis, Mark G.
Simonyan, Vahan
Thompson, Elaine E.
Xu, Ethan Y.
Cradick, Thomas J. http://orcid.org/0000-0002-8489-8318
Gordon, Jennifer
Khalili, Kamel http://orcid.org/0000-0002-6819-5217
Funding for this research was provided by:
Excision Biotherapeutics, San Francisco, CA
Article History
Received: 3 March 2023
Revised: 31 May 2023
Accepted: 28 June 2023
First Online: 17 August 2023
Change Date: 12 January 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41434-023-00438-6
Competing interests
: KK and RK are named inventors on patents that cover the viral gene editing technology that is the subject of this article. KK is a co-founder, board member, scientific advisor, and holds equity in Excision Biotherapeutics, a biotech start-up that has licensed the viral gene editing technology from Temple University for commercial development and clinical trials. THB holds equity and is a member of the scientific advisory board of Excision BioTherapeutics. The authors declare that this work was produced solely by the authors and that no other individuals or entities influenced any aspects of the work including, but not limited to, the study conception and design; data acquisition, analysis and interpretation; and writing of the manuscript.
: This study was approved by BIOQUAL’s IACUC, protocol number 18-036. All animals were maintained at BIOQUAL according to the Association for Assessment and Accreditation of Laboratory Animal Care standards.